Dominican Republic vs Peru: Average cost of drugs for extensively drug-resistant tuberculosis
Dominican Republic
4,000 constant 2022 US$
in 2024
Peru
3,884 constant 2022 US$
in 2024
Dominican Republic rank
17th
Peru rank
18th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Dominican Republic
- Peru
How they compare
Dominican Republic currently reports 4,000 constant 2022 US$ against 3,884 constant 2022 US$ in Peru, a difference of 116 constant 2022 US$.
The two have swapped places 3 times across 7 shared years of data; in 2017 it was Peru ahead.
Dominican Republic ranks 17th and Peru ranks 18th of 56 countries.
Peru has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Dominican Republic | Peru | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 17,073 constant 2022 US$ | 21,788 constant 2022 US$ | 4,715 constant 2022 US$ | Peru |
| 2020s | 2,022 constant 2022 US$ | 5,925 constant 2022 US$ | 3,903 constant 2022 US$ | Peru |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Dominican Republic or Peru?
- Dominican Republic, at 4,000 constant 2022 US$ against 3,884 constant 2022 US$ in Peru as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Dominican Republic and Peru?
- 116 constant 2022 US$, with Dominican Republic ahead.
- How many years of comparable data are there for Dominican Republic and Peru?
- 7 years are reported by both, from 2017 to 2024.
- How do Dominican Republic and Peru rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Dominican Republic ranks 17th and Peru ranks 18th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.